Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) reported 2025 annual results, with operating revenue rising 13.02% YoY to RMB 31.629 billion (USD 4.58 billion) and net profit (recurring) jumping 20.00% to RMB 7.413 billion (USD 1.074 billion). Innovative drugs now dominate revenue mix at 58.34%, with out-licensing emerging as a routine business segment generating RMB 3.392 billion (USD 491 million) through 5 major global deals including GSK, Merck & Co., and IDEAYA Biosciences.
Financial Highlights
Metric
2025 Result
YoY Change
Strategic Significance
Operating Revenue
RMB 31.629 billion (USD 4.58B)
+13.02%
Sustained double-digit growth at scale
Recurring Net Profit
RMB 7.413 billion (USD 1.074B)
+20.00%
Margin expansion from innovation mix
R&D Investment
RMB 8.724 billion (USD 1.263B)
Industry-leading intensity
27.6% of revenue – top-tier global biotech R&D ratio
Innovative Drug Sales
RMB 16.342 billion (USD 2.367B)
+26.09%
58.34% of pharma revenue – transformation complete
Out-Licensing Revenue
RMB 3.392 billion (USD 491M)
New routine segment
10.7% of total revenue – validates global IP value
Forward‑Looking Statements This brief contains forward‑looking statements regarding 2026–2028 product approvals, out-licensing sustainability, and global partnership expansion. Actual results may differ due to NMPA review timelines, competitive dynamics in oncology and metabolic diseases, and geopolitical factors affecting China-origin pharmaceutical exports.-Fineline Info & Tech
By Fineline Cube 